We are presenting a case study of 23 patients ...

We are presenting a case study of 23 patients who have benefited from this therapy. Patients received dosages ranging from 13.5mg to 36mg, with an average of 22mg for a 70kg (150lb) patient. Statistical analysis revealed a clinically relevant P value of <0.005 for the IGF-1 level; as well as a notable P value of <0.010 for total cholesterol and <0.005 for change in total body weight. Our clinical experience demonstrates monthly human growth hormone injections can sustain elevated levels of IFG-1 and promote reversal of pause phenomena in areas such as total cholesterol and total body weight. (See table below)

Measure	# Patients		Mean	Std Dev	Std Error	Min.	Max	P Value
IGF-1	23	Baseline	203.000	100.703	20.998	13	376
		Post Tx	296.130	177.942	37.103	90	600
		Increase	93.130	136.331	28.427	-123	340	P<0.005
Cholesterol	17	Baseline	209.471	34.522	8.373	153	275
		Post Tx	184.412	33.783	8.193	132	246
		Decrease	25.059	34.635	8.400	-18	95	P<0.010
Body Weight	22	Baseline	164.091	30.276	6.455	123	252
		Post Tx	158.136	27.777	5.922	126	233
		Decrease	5.955	7.332	1.563	-10	19	P<0.005

This is just the beginning to the benefits that this treatment modality can offer. We anticipate that the field would follow our footsteps in providing such an efficacious treatment and promoting its positive outcomes for patients.

Articles: [ Prev 6 7 8 9 10 Next ]

• Adult Growth Hormone Deficiency and Human Growth Hormone 
• Linear growth velocity may be as slow as ... 
• Kabi International Growth Study (KIGS) is a ... 
• In contrast, the diagnosis of adult GHD is complex ... 
• Since aging is a multifactorial neuro-endocrine disorder ... 
• In spite of the ongoing debates ... 
• Laboratory values are usually based upon normograms ... 
• Our current knowledge base on growth hormone ... 
• We are presenting a case study of 23 patients ... 
• References